Terpenoids are natural oils made from cannabis fragrance terpenes. Past studies have already confirmed that CBD eases chronic inflammation.
The study concentrated on a twenty question online survey to examine dermatologists' knowledge, attitude and perception of therapeutic CBD.
This study suggests that CBD administered to middle-aged rats with CCH aids in the reduction of neuroinflammation and the enhancement of memory performance.
By looking at these studies as a whole the researchers stated with moderate certainty that CBD reduces seizures among children with drug-resistant epilepsy.
Epidolex is the first cannabis and cannabidiol (CBD)-based drug approved by the FDA and specifically treats Lennox-Gastaut syndrome and Dravet syndrome.
Researchers test CBD's ability to restore functional autophagy, reduce inflammation and positively enhance muscle function.
Cannabis has shown to have anti-inflammatory and anti-hyperalgesia (lowering of pain response) properties, but the exact plant components causing these effects were the target of this study.
A group of researchers from the United States, Canada and Italy conducted a study on rats to determine if CBD could be a viable treatment option for neuropathic pain conditions.
CBD has previously demonstrated immunosuppressant properties which encouraged a new study examining the effectiveness of CBD as a treatment therapy option for MS patients.